BeOne Medicines Says Its Experimental Cancer Therapies Showed 'Promising' Results at ASCO 2026

MT Newswires Live06-01

BeOne Medicines (ONC) said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.

The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.

Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.

BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640955081?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640955081","market":"nz","top_or_hot":-1,"title":"BeOne Medicines Says Its Experimental Cancer Therapies Showed 'Promising' Results at ASCO 2026","media":"MT Newswires Live","content":"<html><body><p> BeOne Medicines (ONC) said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.</p><p>The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.</p><p>Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.</p><p>BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines Says Its Experimental Cancer Therapies Showed 'Promising' Results at ASCO 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines Says Its Experimental Cancer Therapies Showed 'Promising' Results at ASCO 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-01 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BeOne Medicines (ONC) said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.</p><p>The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.</p><p>Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.</p><p>BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640955081","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640955081","pubTimestamp":1780312221,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BeOne Medicines  said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ONC":"百济神州","MDCO":"麦迪逊医药","BK4588":"碎股","BK4526":"热门中概股","BK4585":"ETF&股票定投概念"},"translate_title":"BeOne Medicines表示其实验性癌症疗法在ASCO 2026上显示出“有希望”的结果","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCO":1.5,"ONC":1},"content_text":"BeOne Medicines (ONC) said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640955081","isCrawlerRequest":true}